Summary
DexCom, Inc. (DXCM) has announced that its Chief Executive Officer and Chairman of the Board, Kevin R. Sayer, is taking a temporary medical leave of absence, effective September 14, 2025. This development necessitates a temporary leadership transition to ensure continuity of operations and strategic direction. In response, the Board of Directors has appointed Jacob S. Leach, currently President and Chief Operating Officer, to serve as the interim principal executive officer. Additionally, Mark Foletta, the Lead Independent Director, has been appointed as the interim Chairman of the Board. Investors should note that neither Mr. Leach nor Mr. Foletta will receive additional compensation for these interim roles, signaling a commitment to stable governance during this period. The company has emphasized that Mr. Leach's appointment is not subject to any specific arrangements or understandings with other parties and that he has no material interests in any reportable transactions.
Key Highlights
- 1CEO Kevin R. Sayer has begun a temporary medical leave of absence effective September 14, 2025.
- 2Jacob S. Leach, President and COO, has been appointed interim principal executive officer.
- 3Mark Foletta, Lead Independent Director, has been appointed interim Chairman of the Board.
- 4The interim appointments are effective September 14, 2025.
- 5No additional compensation will be provided to Messrs. Leach and Foletta for their interim roles.
- 6The company has provided assurances regarding Mr. Leach's lack of pre-arranged selection criteria and material interests in disclosed transactions.